Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dYeyCfbwocePsBbFhFbd

October 30, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • Oxford, Menarini join forces to develop antibody-based cancer drugs
    Oxford BioTherapeutics and Menarini agreed to jointly develop antibody-based oncology drugs, and the deal will cover five of OBT's antibody and antibody-drug conjugate programs. Menarini will be in charge of early clinical development and manufacturing. Once the drugs pass proof-of-concept tests, OBT will take over clinical development and marketing of the drugs in North America and Japan, while Menarini will get the rights to develop and sell the drugs in Europe, Asia, the Commonwealth of Independent States and Latin America. The partnership's investment could surpass $1 billion, Menarini said. Genetic Engineering & Biotechnology News (10/29) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
 
  • FDA expedites review of Bayer's regorafenib
    Bayer obtained priority-review status from the FDA for regorafenib as a treatment for gastrointestinal stromal tumors. The drug would be sold as Stivarga and marketed jointly in the U.S. with Onyx Pharmaceuticals. Reuters (10/29) LinkedInFacebookTwitterEmail this Story
  • Coalition aims to standardize clinical trial data reporting
    The FDA joined the Clinical Data Interchange Standards Consortium and the Critical Path Institute to form the Coalition For Accelerating Standards and Therapies to develop and maintain data standards regarding individual diseases and therapeutic areas. CFAST will bring together experts in health care technology, government and the drug industry to develop standards so that data from multiple trials regarding the same therapeutic area or disease can be more easily grouped for analysis and reporting. Express Pharma (10/25) LinkedInFacebookTwitterEmail this Story
  • Other News
Accelerate molecular simulations for your drug discovery research, with Accelrys Discovery Studio ® 3.5!
Designed to address the modeling challenges faced by research scientists, Discovery Studio 3.5 is Accelrys' latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design. Register for our webinar and learn about Accelrys Discovery Studio.
  Company & Financial News 
 
7 keys: Put real-world evidence into action
Life sciences organizations need to know how their therapies work in the real world once clinical trials end. And these seven key components to standardizing real-world data and analytics platforms are how they get started. Read the paper, Institutionalizing Real World Evidence.
ADVERTISEMENT
  Global Developments 
  • Consortium launches France's first cell therapy factory
    The C4C consortium of government agencies and biotechnology companies has established a cell therapy factory in Les Ulis, France. The facility is designed to become a development and manufacturing hub for cell-based treatments. The project received about $100 million from consortium members and almost $40 million from OSEO, France's state innovation agency. In-PharmaTechnologist.com (10/29) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  • Scientists slam recommendation to suspend biotech crop trials in India
    Biotechnologists, agricultural scientists and agribiotech industry leaders criticized the recommendation of a court-appointed panel to suspend trials and commercialization of biotech crops in India for 10 years. The ban could hurt Indian farmers the most as they need to boost food production to meet the needs of the growing population, the scientists said. The recommended moratorium and dismissal of safety data are not based on science, said the former director of the Indian Institute of Science. Business Standard (India) (10/29) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  News from BIO 
  • Ship with FedEx
    FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
A teacher affects eternity; he can never tell where his influence stops."
--Henry Adams,
American journalist, historian, academic and novelist


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information